Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity

Executive Summary

Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.

You may also be interested in...



Polyphor Pursues Promise Of Inhaled Antibiotics To Tackle Lung Infections

An IMI-backed consortium is developing inhaled formulations of the privately held Swiss company's murepavadin and Novartis's tobramycin to reduce infections suffered by bronchiectasis and cystic fibrosis patients.

Actelion Setback Ahead Of J&J Deal Closure

A setback for Actelion – and Johnson & Johnson – as it reports mixed Phase III data for the Clostridium difficile treatment candidate cadazolid.

Flexible 'Menu' Of Antibacterial Development Options Suggested By US FDA Panel

FDA should consider allowing sponsors in challenging area of single species antibacterials more flexibility in study designs, advisory committee suggests, despite disagreement over approaches such as animal models and non-inferiority trials.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel